НОВЫЕ МЕТОДЫ ЛЕЧЕНИЯ ПСОРИАЗА: JAK-ИНГИБИТОРЫ И ИХ РОЛЬ В СОВРЕМЕННОЙ ТЕРАПИИ
Ключевые слова:
псориазАннотация
Данная научная статья представляет собой обзор литературы, посвященный анализу современных методов лечения псориаза с особым вниманием к ингибиторам янус-киназ (JAK-ингибиторам). В работе рассмотрены механизмы действия JAK-ингибиторов, их клиническая эффективность, профиль безопасности, а также их место в алгоритмах лечения
псориаза. Приведены данные ключевых клинических исследований и сравнительный анализ с традиционными методами терапии.
Библиографические ссылки
1. Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide
epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369.
2. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994.
3. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the
immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350.
4. Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev
Immunol. 2014;32:227-255.
5. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment
of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.
6. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK
inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev
Drug Discov. 2017;16(12):843-862.7. Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of Psoriasis: Focus
on Selective TYK2 Inhibitors. Drugs. 2020;80(4):341-352.
8. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation
and immune-mediated disease. Immunity. 2012;36(4):542-550.
9. Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT
signaling in the immune system. Nat Immunol. 2017;18(4):374-384.
10. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling.
Immunol Rev. 2009;228(1):273-287.
11. Xu X, Chen X, Shen M, et al. Switch and its impact on pathogenesis of psoriasis,
II: Th17/Treg ratio, JAK-STAT signaling pathway, and its intervention in the treatment
of psoriasis. Front Immunol. 2022;13:874470.
12. Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from
discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med.
2015;21(7):719-729.
13. Albanesi C, Madonna S, Gisondi P, Girolomoni G. The Interplay Between
Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Front Immunol.
2018;9:1549.
14. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis
of psoriasis. Semin Cutan Med Surg. 2010;29(1):3-9.
15. Galapagos NV. Selective JAK1 inhibition: a promising approach in inflammatory
disease. Front Immunol. 2018;9:1936.
16. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune
responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-4243.
17. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor,
for the treatment of chronic plaque psoriasis: results from two randomized, placebo
controlled, phase III trials. Br J Dermatol. 2015;173(4):949-961.
18. Bachelez H, van de Kerkhof PC, Strohal R, et al. Tofacitinib versus etanercept or
placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non
inferiority trial. Lancet. 2015;386(9993):552-561.19. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2
is efficacious in rodent models of arthritis: preclinical characterization of
INCB028050. J Immunol. 2010;184(9):5298-5307.
20. Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib,
an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe
psoriasis. Br J Dermatol. 2016;174(6):1266-1276.
